NICE guidelines update to include Cytisine
NICE has made the decision to add Cytisine to smoking cessation guideline NG209 following an exceptional review published February 2024.
The update “2024 exceptional surveillance of tobacco: preventing uptake, promoting quitting and treating dependence” will focus on the inclusion of cytisine as a medicinally licensed product to be used as a stop-smoking intervention. The guideline currently states that varenicline, nicotine-containing e‑cigarettes and nicotine replacement therapies (NRT) are more likely to result in people successfully stopping smoking. The available evidence confirms that cytisine has a comparable effect, safety and cost to these recommended products.
